<DOC>
	<DOCNO>NCT01554917</DOCNO>
	<brief_summary>This study intend evaluate safety efficacy Iguratimod patient active Rheumatoid Arthritis .</brief_summary>
	<brief_title>A Study Iguratimod Patients With Active Rheumatoid Arthritis</brief_title>
	<detailed_description>This multi-center , open , single arm study .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Subjects diagnosis RA Subjects active RA time screen Subjects n't use antirheumatic drug use antirheumatic drug 3 month time screen Written informed consent Subjects serious cardiovascular , renal , hematologic endocrine disease Pregnant lactate woman ALT &gt; 1.5×ULN , AST &gt; 1.5×ULN , Cr &gt; 135umol/L WBC &lt; 4×109/L，HGB &lt; 85g/L，PLT &lt; 100×109/L Subjects uncontrolled infection Patients active gastrointestinal disease ( gastric ulcer , etc . ) Allergic study drug History alcoholism Subjects receive live vaccine within 3 month prior study entry Subjects participate clinical study within 3 month prior study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Iguratimod</keyword>
</DOC>